Beam Therapeutics CEO John M. Evans Reports Sale of $1.19 Million in Common Shares

By Public Technologies00:10 (UTC), 17 October 2026 Updated

Beam Therapeutics CEO and director John M. Evans sold 50,000 common shares on October 15-16, 2026.
Sales totaled 25,000 shares at $23.566 on October 15, with another 25,000 shares sold at $23.9838 on October 16.
Evans exercised stock options for 25,000 common shares on each date at $1.03 per share.
Direct common stock holdings stood at 1,047,205 shares following the transactions; indirect holdings totaled 103,000 shares through a trust.
Remaining directly held stock options totaled 155,804, with an exercise price of $1.03.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-424421), on October 16, 2026, and is solely responsible for the information contained therein.